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Drug resistance in Streptococcus pneumoniae, a frequent pathogen in community-acquired pneumonia, is increasing. Ceftaro-
line (active metabolite of ceftaroline fosamil) is a broad-spectrum intravenous cephalosporin with activity in vitro against drug-
resistant Gram-positive organisms. We investigated ceftaroline at 600 mg every 12 h (q12h) (maximum concentration of the free,
unbound drug in serum [fCmax] is 15.2 g/ml, and half-life [T1/2] is 2.5 h) versus ceftriaxone at 1 g q24h (fCmax  23 g/ml,
T1/2  8 h) against six clinical S. pneumoniae isolates in a one-compartment in vitro pharmacokinetic/pharmacodynamic 96-h
model (starting inoculum of 107 CFU/ml). Differences in CFU/ml (at 24 to 96 h) were evaluated by analysis of variance with a
Tukey’s post hoc test. Bactericidal activity was defined as a >3 log10 CFU/ml decrease from the initial inoculum. Ceftaroline
MICs were 0.06, 0.015, <0.008, 0.25, 0.25, and 0.5 g/ml, and ceftriaxone MICs were 0.5, 0.25, 0.25, 4, 4, and 8 g/ml for SP 1477,
SP 669, SP 132, SP 211, SP 90, and SP 1466, respectively. Against the ceftaroline- and ceftriaxone-susceptible strain SP 1477, cef-
taroline displayed sustained bactericidal activity (3 to 96 h, 5.49 log10 CFU/ml) and was significantly (P < 0.012) better than
ceftriaxone (72 to 96 h, 2.03 log10 CFU/ml). Against the ceftriaxone-resistant strains, ceftaroline displayed sustained bacteri-
cidal activity at 96 h and was significantly better than ceftriaxone (SP211 [5.91 log10 CFU/ml, P < 0.002], SP 90 [5.26 log10
CFU/ml, P < 0.008], and SP1466 [5.14 log10 CFU/ml, P < 0.042]). Ceftaroline was the more effective drug and displayed sus-
tained bactericidal activity. Ceftaroline fosamil may provide a therapeutic option to treat ceftriaxone-resistant S. pneumoniae
infections.
Community-acquired pneumonia (CAP) represents a serioushealth care issue, with mortality rates ranging from 1% in
mild disease stages (pneumonia severity index risk classes I and II)
to more than 30% in patients with severe CAP (pneumonia sever-
ity index risk class V) (21). CAP is the 6th leading cause of death in
the United States and the leading cause of death from infectious
disease (22).
Streptococcus pneumoniae is the most frequent pathogen iso-
lated in CAP (15, 26). Although a recent study found a decrease in
invasive pneumococcal disease during 2002 to 2008 compared to
the incidence from 1999 to 2000, a significant increase in penicillin
and cefotaxime resistance has been reported during the 10-year
period (25). It has recently been estimated that more than 40% of
strains are penicillin resistant in some regions of the United States
(14). Similarly, in some European countries, strains of S. pneu-
moniae recovered from invasive disease in adults also demon-
strated an increased antimicrobial resistance profile, with more
than 15% of the isolates being resistant to cefotaxime in France
and more than 20% being resistant to cefotaxime/ceftriaxone
(CRO) in Spain (7, 23). In addition, the introduction of the hep-
tavalent pneumococcal conjugate vaccine (PCV7) has been asso-
ciated with the emergence of multidrug-resistant (MDR) sero-
types, such as serotype 19A (13, 24). Therefore, in addition to the
high mortality rate of pneumococcal infections, the emergence of
MDR S. pneumoniae highlights the need for newer compounds
exhibiting higher activity against MDR isolates.
Ceftaroline (CPT), the active metabolite of the prodrug cef-
taroline fosamil, is a new and broad-spectrum cephalosporin that
displays in vitro activity against methicillin-resistant Staphylococ-
cus aureus (MRSA) and cephalosporin and penicillin-resistant S.
pneumoniae (12, 18). Ceftaroline has demonstrated potent in vitro
activity against bacteremia isolates of MRSA and penicillin-resis-
tant S. pneumoniae recovered from patients with CAP (MIC90s of
2 and 0.25 mg/liter, respectively) (20).
Resistance to -lactam agents is mediated by successive alter-
ations in essential penicillin binding proteins (PBPs). Unlike other
-lactams, ceftaroline displays in vitro activity against penicillin-
and cephalosporin-resistant S. pneumoniae, as it maintains high
affinity for PBP 2X mutants (8, 18, 19). Ceftaroline fosamil is
approved for the treatment of acute bacterial skin and skin struc-
ture infections and community-acquired bacterial pneumonia
caused by susceptible bacteria. Ceftaroline fosamil represents a
potential option for treatment of pneumococcal infections caused
by MDR S. pneumoniae isolates, although further study is needed.
The objective of the study was to investigate the in vitro activity
of ceftaroline at a dosage of 600 mg every 12 h (q12h) against
clinical isolates of S. pneumoniae using a well-established one-
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compartment in vitro pharmacokinetic and pharmacodynamic
(PK/PD) model.
(Results of this study were presented as a poster at the 51st
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, Chicago, IL, 17 to 20 September 2011.)
MATERIALS AND METHODS
Bacterial strains. Six clinical strains of S. pneumoniae (3 ceftriaxone sus-
ceptible [CRO-S] and 3 ceftriaxone resistant [CRO-R]) were evaluated
(obtained from JMI Laboratories, North Liberty, IA). The S. pneumoniae
isolate ATCC 49619 (quality control [QC] MIC range of 0.03 to 0.125
mg/liter for ceftriaxone and 0.008 to 0.03 mg/liter for ceftaroline) was
used for quality control in all susceptibility testing.
Antimicrobial agents. Microbiologically active ceftaroline (CPT) (lot
number FMD-CEF-035) was supplied by Forest Laboratories (New York,
NY). Ceftriaxone was commercially purchased from Sigma-Aldrich (St.
Louis, MO). Stock solutions of each antibiotic were prepared fresh daily.
Media. All susceptibility testing and in vitro PK/PD models were per-
formed using Todd Hewitt broth (Difco Laboratories, Detroit, MI) with
0.5% yeast as previously described for experiments evaluating S. pneu-
moniae isolates (4). Colony counts and emergence of resistance were de-
termined using Mueller-Hinton agar with 5% sheep blood without and
with drug at 3 the baseline MIC, respectively.
Susceptibility testing. MICs were determined by a broth microdilu-
tion technique, using Todd-Hewitt broth supplemented with 0.5% yeast
extract (medium used in PK/PD model) and an inoculum of 5  106
CFU/ml. MIC trays were incubated for 24 h at 37°C in 5% CO2.
One-compartment in vitro PK/PD model. An in vitro PK/PD 96-h
model consisting of a 210-ml 1-compartment glass chamber with multi-
ple ports for the addition and removal of growth medium, delivery of
antibiotics, and collection of samples was utilized to assess ceftaroline and
ceftriaxone activities. The apparatus was prefilled with fresh medium,
antibiotics were administered as boluses, and all experiments were per-
formed in duplicate to ensure reproducibility. Prior to each experiment,
lawns of overnight growth from three Mueller-Hinton agar plates supple-
mented with 5% lysed sheep blood were introduced into the one-com-
partment model system (yielding 107 CFU/ml) 30 min prior to each sim-
ulation to allow the microorganism to adapt to the medium. The model
was placed in a room incubator at 37°C for the duration of the experi-
ments. Peristaltic pumps (Masterflex; Cole-Parmer Instrument Com-
pany, Chicago, IL) were used to continually replace antibiotic-containing
medium with fresh, antibiotic-free medium (at a rate simulating the
plasma clearance and half-lives of the antibiotics). To maintain similar
growth conditions for all tested regimens, the pump rate was set to the rate
for the antibiotic with the fastest clearance (ceftaroline in this study). A
second chamber was utilized for all experiments with ceftriaxone, and
ceftriaxone was supplemented into this chamber to maintain the longer
half-life (3). Simulated regimens included 600 mg intravenous (i.v.)
ceftaroline every 12 h (maximum concentration of the free, unbound
drug in serum [fCmax], 15.2 g/ml [i.e., 80% of 19 g/ml, based on
20% protein binding]; average half-life, 2.5 h) and 1 g i.v. ceftriaxone
every 24 h (fcmax, 23 g/ml [85% protein binding]; average half-life, 8
h) (1, 11).
Pharmacokinetic analysis. Antibiotic concentrations were deter-
mined from samples drawn from each model system at 0, 1, 2, 3, 6, 24, 27,
30, 48, 54, 72, and 96 h in duplicate. Samples were stored at 70°C until
analysis. Ceftaroline and ceftriaxone concentrations were determined by
bioassay using Bacillus subtilis ATCC 6633 and Escherichia coli ATCC
25922. Blank 1/4-in. disks were spotted with 10 l of the standards (2.5,
10, and 40 g/ml of ceftaroline or 5, 10, and 20 g/ml of ceftriaxone) or
samples. Each standard was tested in duplicate by placing the disk on
Mueller-Hinton agar plates, which were preswabbed with a 0.5 McFarland
suspension of the test organism. Plates were incubated at 37°C for 18 to 24
h, at which time the zone sizes were measured. This assay was linear over
the range tested (r2  0.95; between-day and intraday coefficient of vari-
ation for low, medium, and high standards, 12.8%). Similar to other
cephalosporins, the PK/PD index that best correlates with efficacy for
ceftaroline is free-drug percentage of time above the MIC (r2  83 to 88%)
(2). Ceftaroline and ceftriaxone free-drug peak and trough concentra-
tions, times above the MIC (or multiples of the MIC), and half-lives were
calculated using concentration-time plots of the model samples. The area
under the concentration-time curve from 0 to 24 h was calculated by using
the linear trapezoid method and the PKANALYST program (version 1.10;
MicroMath Scientific Software, Salt Lake City, UT).
Pharmacodynamic analysis. Samples (approximately 1.5 ml each)
from each model were collected at 0, 3, 6, 24, 27, 30, 48, 54, 72, and 96 h.
Samples were then serially diluted in 0.9% sodium chloride. Bacterial
counts were determined by drop plating 10-l amounts of each diluted
sample on Mueller-Hinton agar supplemented with 5% blood. In order to
minimize antibiotic carryover, all samples were diluted at least 10-fold
before plating or plated following vacuum filtration (direct sample of 1 ml
washed through a 0.45-m-pore-size filter with normal saline) for dilu-
tions with predicted concentrations close to or greater than the MIC for
the tested organism. Plated samples were incubated at 37°C with 5% CO2
for 24 h, at which point colony counts were determined. The limit of
detection for this method of colony count determination is 1 log10 CFU/
ml. In vitro time-kill curves were determined by plotting mean colony
counts (log10 CFU/ml) versus time. Bactericidal activity (99.9% kill) was
defined as a 3 log10 CFU/ml reduction in colony count from the starting
inoculum using linear regression if the r2 was 0.95 or by visual inspec-
tion.
Detection of resistance. Samples (100 l each) from the 96-h time
point were plated on the day of collection onto Mueller-Hinton agar sup-
plemented with 5% blood containing an antibiotic concentration (of the
respective model run) of 3 times the MIC for each organism. Plates were
incubated for up to 48 h at 37°C with 5% CO2 in order to monitor the
development of resistance and visually inspected for the growth of resis-
tant subpopulations after 24 and 48 h of incubation. The MIC for each
colony recovered onto drug-containing plates was determined by the
broth microdilution method as described above.
Statistical analysis. Differences in outcome (log10 CFU/ml) between
regimens (including growth control) at 24, 48, 72, and 96 h were deter-
mined using one-way analysis of variance with Tukey’s post hoc test. For
all experiments, a P value of 0.05 was considered indicative of statistical
significance. All statistical analyses were performed using SPSS (version
18.0; SPSS, Inc., Chicago, IL).
RESULTS
MICs and serotypes for the six S. pneumoniae isolates studied are
displayed in Table 1. The pharmacokinetic parameters achieved
(average  standard deviation) for ceftaroline (half-life [T1/2],
2.38  0.3 h; maximum concentration of the free, unbound drug
in serum [fCmax], 15.2  2 g/ml; fCmin, 0.46  0.08 g/ml) and
for ceftriaxone (T1/2  8.2  1.2 h, fCmax  19.6  1.5 g/ml,
fCmin  2.54  0.34 g/ml) were well matched with the targeted
values. The pharmacodynamic parameters achieved are also dis-
played in Table 1. As can be seen, ceftaroline free time above the
MIC (fT  MIC) ranged from 97.7 to 100% and fT  4 MIC
ranged from 59 to 100%. For the CRO-S strains SP 1477, SP 669,
and SP 132, ceftriaxone fT  MIC and fT  4 MIC were 100%.
In contrast, the ceftriaxone fT  MIC and fT  4 MIC achieved
for CRO-R SP 1466 (CRO MIC, 8 g/ml) were 44% and 0%,
respectively. For CRO-R SP 211 and SP 90 (CRO MIC 4 g/ml),
the ceftriaxone fT  MIC and fT  4 MIC achieved were 78.4%
and 10%.
The activity of ceftaroline and ceftriaxone against the six iso-
lates tested is displayed in Fig. 1. Against the CRO-R strains SP
1466, SP 211, and SP 90, ceftriaxone failed to maintain bactericidal
activity at 96 h (Fig. 1A to C). In contrast, ceftaroline displayed
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rapid (Table 1) and sustained bactericidal activity against the three
CRO-R strains (Fig. 1). Against CRO-S SP 1477 (CPT MIC  0.06
g/ml, CRO MIC  0.5 g/ml) ceftaroline displayed rapid and
sustained bactericidal activity, while regrowth occurred periodi-
cally with ceftriaxone between 24 h and 96 h (Fig. 1D). Ceftaroline
was significantly more active and sustained than ceftriaxone in
decreasing colony counts from 72 to 96 h against CRO-R SP 1466
(P  0.042), SP 211 (P  0.002), and SP 90 (P  0.008) and against
CRO-S SP 1477 (P  0.012). As for SP 1477, ceftriaxone treatment
of SP 211, SP 90, and SP 1466 resulted in periodic regrowth and
killing over the 24- to 96-h dosing period, unlike the sustained
bactericidal activity observed for ceftaroline. Against the 2 CRO-S
strains, SP 669 and SP 132, both ceftaroline and ceftriaxone dis-
played rapid (Table 1) and sustained bactericidal activity (Fig. 1E
and F). No mutant was recovered for either ceftaroline or ceftri-
axone at 3 MIC at 96 h.
DISCUSSION
In this study, we evaluated the in vitro activity of ceftaroline versus
that of ceftriaxone against six clinical isolates of S. pneumoniae of
various serotypes and degrees of susceptibility to ceftriaxone. As
would be expected, ceftaroline and ceftriaxone both displayed
rapid bactericidal activity against two of the CRO-S strains, SP 669
and SP 132. A 3-log10 reduction in CFU/ml was achieved at 3 h,
and a maximal effect of a 6-log10 reduction in CFU/ml was
achieved by the end of the experiment. This is consistent with both
ceftaroline and ceftriaxone exhibiting time above the MIC, 2
MIC, and 4 MIC of 100% of the dosing interval for both organ-
isms. The activities of ceftaroline and ceftriaxone against the third
cephalosporin-susceptible strain (SP 1477) are interesting, as this
organism has slightly higher MIC values and both antibiotics were
above 4 the MIC for 100% of the dosing interval. The ceftaroline
kill kinetics were slightly slower for this strain than for SP 669 and
SP 132 but were still bactericidal at 3 h and at detection limits by 6
h. The decrease in CFU counts was maintained for the 96 h of the
experiment. Ceftriaxone also reduced counts to detection limits;
interestingly, this was followed by a bactericidal regrowth pattern
over the duration of the 96 h. This pattern was also observed with
CRO for the 3 CRO-R strains. For the two isolates with CRO MICs
of 4 g/ml, the times above the 2 and 4 MIC were approxi-
mately 44 and 10% of the dosing interval. For these two isolates
(SP 90 and SP 211), ceftriaxone decreased the inoculum counts
but failed to reach detection limits, unlike with SP 1477, and re-
growth occurred to a greater extent than with SP 1477. The largest
bactericidal regrowth pattern with ceftriaxone was observed
against SP 1466 (CRO MIC  8 g/ml) and corresponded to free
times above the 2 and 4 MIC of 10% and 0%. Against the
CRO-R strains, ceftaroline also displayed rapid and sustained bac-
tericidal activity, with times above the MIC of 97 to 100% of the
dosing interval.
The results from this in vitro study support the results of a
previous in vivo study that examined the efficacy of both ceftaro-
line and ceftriaxone in an immunocompetent pneumococcal
pneumonia rabbit model against three strains: penicillin suscep-
tible and CRO-S, penicillin intermediate and CRO-S, and penicil-
lin resistant and CRO-R (6). In that study, the inoculum decreases
in the lungs at 48 h for the two CRO-S strains were over 6 log10
CFU/g for both ceftaroline and ceftriaxone. For the CRO-R strain,
ceftaroline retained substantial bactericidal activity in the lung
while ceftriaxone produced only a small decrease in log10 CFU/g
that was not statistically different from the results for controls.
Ceftaroline total-drug and free-drug times above the MIC of 40%
and 25% were associated with complete eradication. Total drug
time above the MIC for ceftriaxone did not appear to predict
activity, with 100% fT  MIC failing to achieve eradication in the
majority of animals. The findings by Croisier-Bertin et al. (4) ap-
pear similar to those of our current study in which ceftriaxone
time above the MIC or multiples of the MIC did not appear to fully
explain the activity in the CRO-R strains and in SP 1477.
The limitations of this study include the short study duration
of 4 days as opposed to 5 to 7 days for clinical treatment of com-
munity-acquired pneumonia. Additionally, the growth condi-
tions for S. pneumoniae in the in vitro PK/PD model are different
from those in the human lung and therefore give both tested an-
tibiotics an artificial advantage. As the in vitro PK/PD model uti-
TABLE 1 MICs for Streptococcus pneumoniae isolates and analysis of pharmacokinetic parameters achieved
Drug and isolate




% of dosing interval at fT :
MIC 2 MIC 4 MIC
Ceftaroline
SP 1466 (19F) 0.5 5.14 1.99 97.7 77.9 59
SP 211 (19A) 0.25 5.91 4.28 100 97.7 77.9
SP 90 (35B) 0.25 5.26 2.15 100 97.7 77.9
SP 1477 (6C) 0.06 5.49 2.15 100 100 100
SP 669 (7F) 0.015 6.09 1.57 100 100 100
SP132 (3) 0.008 5.94 1.44 100 100 100
Ceftriaxone
SP 1466 (19F) 8 2.25 NA 44 10 0
SP 211 (19A) 4 0.36 NA 78.4 44 10
SP 90 (35B) 4 2.35 NA 78.4 44 10
SP 1477 (6C) 0.5 2.03 NA 100 100 100
SP 669 (7F) 0.25 6.00 1.86 100 100 100
SP132 (3) 0.25 5.79 1.86 100 100 100
a Log10 CFU/ml is the change in log10 CFU/ml from the starting inoculum as assessed at 96 h.
b Times to 99.9% reduction in CFU/ml counts relative to starting inoculum are indicated for those isolates showing sustained bactericidal activity (i.e., 99.9% reduction in CFU/
ml as assessed at 96 h). NA, not applicable as sustained bactericidal activity was not observed by 96 h.
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lized in this study was a one-compartment model, the target con-
centrations were those of the serum and did not take into account
time or extent of penetration into the lung tissue. Additionally,
only three CRO-R strains were tested in this study (such strains are
relatively rare clinically).
The treatment of community-acquired pneumonia will con-
tinue to represent a clinical challenge as drug resistance is continu-
ing to increase. Recent analysis of amoxicillin-clavulanate, peni-
cillin, and ceftriaxone susceptibilities in S. pneumoniae isolates
from 1998 to 2009 revealed increasing resistance against all three
antibiotics to more than 10% of isolates (16). Ceftaroline fosamil
has been shown to be effective and well tolerated in the treatment
of community-acquired pneumonia in two large, randomized tri-
als, FOCUS I and FOCUS II (NCT00621504 and NCT00509106)
(9, 10, 17). Ceftaroline had higher clinical cure rates than ceftri-
axone for CAP caused by S. pneumoniae in FOCUS I (88.9% ver-
FIG 1 In vitro killing in the one-compartment pharmacokinetic/pharmacodynamic model. Filled circles, growth control; filled squares, 600 mg i.v. ceftaroline
q12h; open triangles, 1 g i.v. ceftriaxone q24h.
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sus 66.7%) and FOCUS II (83.3% versus 70.0%) (10, 17). In these
two trials, however, only one isolate with intermediate suscepti-
bility to penicillin was recovered (5). There may, therefore, be
some clinical relevance associated with ceftriaxone-susceptible
strains, such as SP 1477, in which ceftriaxone fails to maintain
bactericidal activity and is significantly worse than ceftaroline. At
this time, therefore, there is limited clinical data on the utility of
ceftaroline fosamil to treat community-acquired pneumonia
caused by these -lactam-resistant pneumococcal strains. The
combination of the in vitro data from this study, the in vivo data
from the rabbit pneumonia model, and the overall safety and ef-
ficacy in clinical trials on community-acquired pneumonia sup-
port the clinical use of ceftaroline fosamil and its potential to treat
pneumonia infections caused by CRO-resistant S. pneumoniae.
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